Osivax Employee Directory
Biotechnology ResearchAuvergne-rhône-alpes, France51-200 Employees
Osivax is a clinical-stage biopharmaceutical company focused on developing broad-spectrum influenza vaccines that aim to generate robust T-cell responses alongside strong B-cell responses. Its lead candidate, OVX836, is in Phase 2b trials and has been tested in thousands of volunteers, with data described as encouraging in terms of efficacy. The company seeks to enhance seasonal flu vaccines by combining OVX836 with standard vaccines to broaden protection across influenza A strains, and it collaborates with global health agencies and major pharmaceutical partners to pursue preventive solutions for seasonal and pandemic influenza. Osivax operates from Lyon, France, and positions itself within the biotechnology research sector by pursuing a platform that supports vaccines targeting highly mutating infectious viruses, with plans to expand into other infectious diseases through collaborations. In addition to developing its core influenza program, the firm has pursued related vaccine candidates and preclinical work, reflecting an approach centered on leveraging immune responses to achieve broader protection.
1-888-653-2347 
support@leadiq.com 
